Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

Real-world MitraClip Impact in Secondary MR: Reassuring for Some, Not All

News Daily News

Real-world MitraClip Impact in Secondary MR: Reassuring for Some, Not All

Michael O'Riordan

September 18, 2023

One in Six COAPT Patients Had Malnutrition: TEER Helped Regardless

News Daily News

One in Six COAPT Patients Had Malnutrition: TEER Helped Regardless

June 12, 2023

Latest-Generation MitraClip Devices Make Strides Against Residual MR

News Conference News TVT 2023

Latest-Generation MitraClip Devices Make Strides Against Residual MR

June 09, 2023

Solid Anchoring, Good Echo Results With Transapical TMVR at 2 Years

News Conference News TVT 2023

Solid Anchoring, Good Echo Results With Transapical TMVR at 2 Years

Michael O'Riordan

June 09, 2023

MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients

News Conference News EuroPCR 2022

MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients

Michael O'Riordan

May 20, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

Is COAPT Designed to Fail? Experts Debate Treatment Timing in Severe Functional MR

News Conference News CRT 2018

Is COAPT Designed to Fail? Experts Debate Treatment Timing in Severe Functional MR

Michael O'Riordan

March 05, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.